What's new?
16/05/2019

Oversubscribed round to bring first products powered by enzymatic DNA synthesis technology to market

Paris, May 16, 2019. Sofinnova Partners, a leading European venture capital firm specialized in the life sciences, today announced that its portfolio company DNA Script, an industry leader in the manufacturing of synthetic nucleic acids using proprietary enzymatic technology, has raised $38.5 million in Series B financing. New shareholders LSP and BPIFrance joined the round, alongside existing shareholders Kurma Partners, Idinvest Partners, Illumina Ventures, and M Ventures (the corporate venture arm of Merck KGaA). Sofinnova Partners was the first institutional investor in DNA Script in 2016.

DNA Script is the world’s leading company in manufacturing synthetic nucleic acids using enzymatic technology. Founded in 2014 in Paris, the company aims to accelerate innovation in life sciences and technology delivering rapid, affordable, and high-quality DNA. Sixty years after the discovery of DNA, DNA Script’s revolutionary approach leverages billions of years of nature’s evolution in synthesizing DNA to enable genome scale synthesis.

The company offers a novel biochemical process for DNA and RNA synthesis, a fundamental tool used in biology research. At a recent academic conference, DNA Script presented its ability to synthesize 200nt of DNA with remarkable accuracy. This innovation may be used in numerous applications, including electronic data storage, by leveraging unprecedented capabilities of the molecule to store information. The fundraising allows DNA Script to further develop its unique enzymatic technology and nucleotide chemistry platform, and deliver the promise of same-day results.

Joško Bobanović, Partner at Sofinnova Partners, said: “We are excited that DNA Script, which we have backed from its first round of financing, was able to raise such a significant round. The company continues to deliver on its plan, and is now funded by a group of likeminded investors who support the team’s vision of creating a business that enables new applications for synthetic DNA and RNA in areas including drug discovery and development, agriculture, and industrial and food technologies.”

“Sofinnova Partners has been an excellent partner from a very early stage, just after the inception of our company,” said Thomas Ybert, CEO of DNA Script. “Since then, they have helped us on a daily basis to build DNA Script from the ground up. The team brings a strong expertise in the technology as well as one of the broadest global networks in the industry. Importantly, they also provide unconditional support and coaching to our entrepreneurs – whatever the challenge at hand,” he said.

This new funding reaffirms Sofinnova Partners’ investment strategy in the industrial biotech field, initiated in 2009. As a pioneer in this emerging and rapidly growing sector, Sofinnova Partners has a portfolio of 14 industrial biotech companies, backed through two dedicated funds: Sofinnova Green Seed Fund, which raised €22.5M in 2012, and Sofinnova IB I, which raised €125M in 2017.

About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims to accelerate innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script’s approach leverages billions of years of natural evolution to enable genome-scale synthesis. The company’s technology has the potential to greatly accelerate the development of new therapeutics, enhanced diagnostics, sustainable chemical production, improved crops and DNA data storage.
www.dnascript.co

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Headquartered in Paris, France, the firm brings together a team of professionals from all over Europe, the U.S. and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information: http://sofinnovapartners.com/.

Press contact for Sofinnova Partners

International
Kate Barrette
RooneyPartners LLC
kbarrette@rooneyco.com

France
Anne Rein
S&I
+ 33 6 03 35 92 05
anne.rein@strategiesimage.com

04/03/2019
04/03/2019
26/02/2019

New York, US and Vienna, Austria, February 26, 2019 – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has completed a $37.4 million (€33.2 million) series D financing.
The investment was led by Redmile Group with participation of additional new investors Invus and Samsara BioCapital, as well as a number of current investors.
The new funding will be primarily used to progress the clinical development of HOOKIPA’s lead development programs, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase 2 clinical trial in patients awaiting kidney transplantation as well as HB-201 and HB-202, the Company’s lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers. In addition, HOOKIPA plans to apply its arenavirus platform to develop additional novel immuno-oncology product candidates.
Joern Aldag, Chief Executive Officer of HOOKIPA said: “We are pleased that this outstanding group of new and current investors supported this financing, which enables us to advance clinical development of our lead development programs. This financing also supports the potential and uniqueness of our novel technology platform and reinforces us in our mission to reprogram the immune system to combat infectious diseases and cancer”.

About HOOKIPA
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.
HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.
Find out more about HOOKIPA online at www.hookipapharma.com.
*Registered in Europe; Pending in the US.

HOOKIPA
Nina Waibel
Head of Communications
Nina.Waibel@HookipaPharma.com

Media enquiries
Sue Charles/ Ashley Tapp
Instinctif Partners
Hookipa@Instinctif.com
+44 (0)20 7457 2020

26/02/2019

New York, US and Vienna, Austria, February 26, 2019 – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has completed a $37.4 million (€33.2 million) series D financing.
The investment was led by Redmile Group with participation of additional new investors Invus and Samsara BioCapital, as well as a number of current investors.
The new funding will be primarily used to progress the clinical development of HOOKIPA’s lead development programs, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase 2 clinical trial in patients awaiting kidney transplantation as well as HB-201 and HB-202, the Company’s lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers. In addition, HOOKIPA plans to apply its arenavirus platform to develop additional novel immuno-oncology product candidates.
Joern Aldag, Chief Executive Officer of HOOKIPA said: “We are pleased that this outstanding group of new and current investors supported this financing, which enables us to advance clinical development of our lead development programs. This financing also supports the potential and uniqueness of our novel technology platform and reinforces us in our mission to reprogram the immune system to combat infectious diseases and cancer”.

About HOOKIPA
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.
HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.
Find out more about HOOKIPA online at www.hookipapharma.com.
*Registered in Europe; Pending in the US.

HOOKIPA
Nina Waibel
Head of Communications
Nina.Waibel@HookipaPharma.com

Media enquiries
Sue Charles/ Ashley Tapp
Instinctif Partners
Hookipa@Instinctif.com
+44 (0)20 7457 2020

25/02/2019

Our managing partner and chairman, Antoine Papiernik, on @CNBC giving his predictions for what’s next in #biotech: https://cnb.cx/2VgRL3H #venturecapital

18/02/2019

New York, US and Vienna, Austria, February 15, 2019– HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors.

Mr. Kelly is a former senior executive of Amgen, Inc. currently acting as Founder & President of Sentry Hill Partners, LLC., who looks back on more than two decades of executive experience in senior leadership roles in the life sciences industry. Prior to retiring from operational management he held various strategic finance and operations positions at Amgen, including the role of acting CFO of Amgen in 2010 and 2014 and positions at Biogen, Tanox and Monsanto Life Sciences. Throughout his career in pharmaceutical operations,
Mr. Kelly has held a variety of strategic finance leadership roles at the Board and Committee level which have successfully led to transformation, restructuring, and integration in environments of rapid innovation and change.

“It is a great pleasure to welcome Michael A. Kelly to HOOKIPA’s Board of Directors. His financial expertise, gained over many years in numerous roles in many highly regarded life science companies will add great value to the governance and the future development of our Company,” said Joern Aldag, HOOKIPA’s Chief Executive Officer.

Mr. Kelly is currently a member of the Board of Directors and serves on the Finance Committee for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. He also previously served as a member of the Board of Trustees at Viewpoint School.

Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance & Industrial Relations.

Commenting on his appointment, Michael A. Kelly said: “HOOKIPA has built a strong investor base to fund their convincing and unique pipeline and technology platform. I look forward to working with the Board of Directors and HOOKIPA’s experienced Management Team to further advance the Company’s success.”

About HOOKIPA
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a
Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.

TheraT® and VaxWave® are not approved anywhere globally and their safety and efficacy have not been established.

Find out more about HOOKIPA online at www.hookipapharma.com.

*Registered in Europe; Pending in the US.

Investors
Alexandria Center for Life Sciences
430 East 29th Street, 14th Floor (cross street 1st Ave and 29th St) New York, NY 10016
St Marx Vienna BioCenter
Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria
E: office@hookipapharma.com
T: +43 1 890 63 60
F: +43 1 890 63 60 399
Privacy Policy
Legal Notice
© Hookipa Pharma Inc.

12/02/2019

Dans le but d’offrir aux industriels une alternative fiable à l’utilisation de dérivés du pétrole, AFYREN a validé à l’échelle pré-industrielle la production d’acides organiques biosourcés pouvant être utilisés dans de multiples applications. La société démarre aujourd’hui la phase industrielle de son développement en sécurisant un financement global de 60 millions d’euros incluant une augmentation de capital de 21 millions d’euros.

Clermont-Ferrand, le 12 février 2019 – AFYREN, producteur de molécules d’intérêt biosourcées à partir de technologies fermentaires, vient de finaliser une levée de fonds de 21 millions d’euros, portée par Sofinnova Partners et Valquest Partners et réunissant aux côtés des actionnaires historiques AFY Partners et Sofimac Régions (Sofimac et les fonds Jérémie Innovation 1 et 2), les fonds Supernova, Crédit Agricole Création ainsi que le Crédit Agricole Centre France. Cette augmentation de capital est associée à un programme de financement de la première usine d’AFYREN, dont les études d’implantation ont déjà débuté. Le plan stratégique prévoit que ce financement de 60 millions d’euros permette à AFYREN de mener son projet industriel jusqu’à la commercialisation.

Pour Nicolas Sordet, Président d’AFYREN : « Ce plan de financement conséquent vient couronner le parcours exceptionnel de nos équipes, qui ont progressivement franchi avec succès toutes les étapes de notre ambitieux projet. Nous détenons aujourd’hui une technologie efficace à une échelle pré-industrielle sur laquelle nous travaillons depuis plusieurs années et qui nous a permis de livrer des lots test à nos premiers clients. Nos produits biosourcés font déjà l’objet d’un fort intérêt de la part d’entreprises de premier plan, et nous abordons la phase d’industrialisation avec confiance et enthousiasme. »

La technologie brevetée d’AFYREN permet de produire des molécules organiques, jusqu’à présent quasiexclusivement issues du pétrole, à partir de différents types de co-produits agro-industriels sans concurrencer la chaîne de production alimentaire et sans générer de déchets. AFYREN transforme ainsi dans une approche d’économie circulaire, différents types de biomasse en sept acides organiques différents. Les niveaux de pureté atteints et leur naturalité permettent de cibler des marchés aussi exigeants que la cosmétique, les arômes et parfums, la nutrition humaine et animale ou encore la chimie fine.

Jérémy Pessiot, fondateur d’AFYREN et en charge de la technologie déclare : «La pertinence de notre technologie réside fondamentalement dans sa capacité à associer l’écologie avec une performance économique. De fait notre engagement est sans compromis entre le respect de l’environnement, notamment la réduction des émissions de CO2, et la compétitivité permettant ainsi aux industriels de substituer des produits issus du pétrole par nos molécules naturelles. C’est ce que nos clients demandent et ce que nos investisseurs apprécient. »

« Nous suivons AFYREN depuis longtemps et avons été impressionnés par ce qu’ils ont été capables d’accomplir ces 18 derniers mois. Avec ce tour de financement, AFYREN a maintenant les moyens humains et financiers d’industrialiser sa Technologie » confirme Michael Krel, Principal chez Sofinnova Partners, qui ajoute : « Ce projet est un bon exemple de la philosophie des fonds de biotechnologies industrielles de

Sofinnova : permettre à des entrepreneurs d’apporter des solutions économiques plus durables à des problèmes globaux ».

AFYREN communiquera plus précisément dans les prochaines semaines sur la suite de son plan de financement et la création de sa filiale industrielle.

A propos d’AFYREN
Pour répondre au besoin croissant des industriels de réduire l’utilisation des dérivés pétroliers dans leur chaîne de production, AFYREN produit des biomolécules issues de la revalorisation de biomasse nonalimentaire, largement utilisées dans les secteurs de la cosmétique, des arômes et parfums, de la nutrition humaine et animale et de la chimie fine. Cette production de carbone renouvelable qui s’inscrit résolument dans une économie circulaire est réalisée grâce à des technologies fermentaires brevetées au niveau mondial, fruit de 7 années de recherche.
Fondée en 2012 par Régis Nouaille et Jérémy Pessiot, AFYREN réunit 15 collaborateurs sur ses sites de Lyon et Clermont-Ferrand. AFYREN est lauréate du Concours Mondial d’Innovation 2030 dans la catégorie « Protéines végétales et chimie du végétal » et a été nommée ambassadrice de la French Tech – Chimie verte à la COP21. AFYREN est accompagnée dans son développement par le Conseil Régional d’Auvergne, Bpifrance, le FEDER et l’ADEME.
afyren.com

Contacts
AFYREN
Nicolas Sordet, Président d’AFYREN
contact@afyren.com
+33 4 73 86 91 84
Calyptus
Mathieu Calleux / Gregory Bosson
afyren@calyptus.net
+33 1 53 65 68 68

12/02/2019

In order to offer industrial firms a reliable alternative to using acids based on oil derivatives, AFYREN has confirmed the production of bio-based organic acids on a pre-industrial scale for use with multiple applications. Today, AFYREN is launching its industrial development phase after securing total financing of 60 million euros, including a 21 million euro capital increase.

Clermont-Ferrand (France), February 12, 2019 – AFYREN, which produces high-value bio-based building blocks to manufacture acids using fermentation technologies, has just completed a 21 million euro round of fundraising, led by Sofinnova Partners and Valquest Partners, bringing on board Supernova, Crédit Agricole Création and Crédit Agricole Centre France alongside its historical shareholders AFY Partners and Sofimac Régions (Sofimac and the Jérémie Innovation 1 and 2 funds). This capital increase is combined with a program to finance AFYREN’s first plant, for which design and development plans are already underway. In line with its established strategy, this 60 million euro financing package will enable AFYREN to take its industrial project forward through to full commercialization.

For Nicolas Sordet, AFYREN’s CEO: “This major financing plan is an outstanding recognition of the exceptional journey undertaken by our teams, who have gradually and successfully completed all the stages of our ambitious project. Today, we possess good pre-industrial phase technology that we have been working on for several years and that has enabled us to deliver test batches to our first customers. Our biobased products are already generating strong interest among leading businesses, and we are moving into the industrialization phase with confidence and enthusiasm”.

AFYREN’s proprietary technology makes it possible to produce organic building blocks, previously obtained almost exclusively from petroleum products, using different types of agro-industry products without competing with the food production chain and without generating waste. Using a circular economy, AFYREN transforms different types of biomass into seven different organic acids. Thanks to the organic acids’ levels of purity and their natural characteristics, AFYREN is able to target markets that require very high standards of quality, from cosmetics to flavors and fragrances, human and animal nutrition, and even fine chemicals.
For Jérémy Pessiot, AFYREN’s founder in charge of the technology: “The relevance of our technology is fundamentally linked to its ability to combine ecology and economic performance. We are firmly committed to providing a 1st class environmental profile, particularly in terms of reducing CO2 emissions, and also competitiveness, enabling industrial customers to replace petroleum-based products with our natural building blocks. This is what our customers require and what our investors appreciate”.

Michael Krel, Principal at Sofinnova Partners, confirmed: “We have been following AFYREN for a long time, and we have been impressed with their achievements over the last 18 months. With this round of financing, AFYREN now has the human and financial resources needed to industrialize its technology”. “This project is an outstanding example of the philosophy behind Sofinnova’s industrial biotechnology funds: enabling entrepreneurs to deliver more sustainable economic solutions to global issues”.

AFYREN will release further details on its financing plan and the setting up of its industrial subsidiary over the coming weeks.

About AFYREN
In order to meet the growing needs of industrial firms to reduce the use of petroleum-based derivatives across their production chains, AFYREN produces bio-molecules, derived from the recovery of non-food biomass, that are widely used in the cosmetics, flavors and fragrances, human and animal nutrition, and fine chemicals sectors. This renewable carbon production, aligned with the circular economy, is achieved using fermentation and downstream proprietary technologies, built up through seven years of research and development.
Founded in 2012 by Régis Nouaille and Jérémy Pessiot, AFYREN has 15 employees at its sites in Lyon and Clermont-Ferrand. AFYREN won the 2030 Worldwide Innovation Challenge in the “plant proteins and plant chemistry” category, and was a French Tech – Green Chemistry ambassador at COP21. AFYREN’s development is being supported by the Auvergne Regional Council, Bpifrance, the European Regional Development Fund (ERDF) and the French Environment and Energy Management Agency (ADEME). afyren.com

Contacts
AFYREN
Nicolas Sordet, CEO
contact@afyren.com
+33 4 73 86 91 84
Calyptus
Mathieu Calleux / Gregory Bosson
afyren@calyptus.net
+33 1 53 65 68 68

31/01/2019

Paris, 31 janvier 2019. Inotrem S.A., une société de biotechnologie spécialisée dans le contrôle de la réponse immunitaire lors de maladies inflammatoires aigües, telles que le choc septique, annonce aujourd’hui la signature d’un accord de licence avec quatre organismes de recherche majeurs, selon les termes duquel Inotrem obtient les droits mondiaux exclusifs pour le biomarqueur soluble TREM-1 (sTREM-1) pour les maladies cardiovasculaires, et en particulier pour l’infarctus du myocarde. Les quatre partenaires académiques sont les universités de Lorraine et Sorbonne, l’Inserm et l’AP-HP.
Désormais, Inotrem détient les droits exclusifs pour sTREM-1 dans le choc septique et les maladies cardiovasculaires. Cet accord permettra à Inotrem de commercialiser ou sous-licencer tous les tests développés pour sTREM-1 dans ces deux indications thérapeutiques.
Jean-Jacques Garaud, Président d’Inotrem, indique : “Cet accord de licence marque une étape cruciale de notre développement. Il nous permet d’étendre notre franchise sur TREM-1 du sepsis aux maladies cardiovasculaires et ainsi consolider notre portefeuille de propriété intellectuelle sur la voie TREM-1, à la fois en tant qu’agent thérapeutique et dans une perspective de médecine personnalisée”.
Pr Hafid Ait Oufella, chef d’équipe “Méchanismes immuno-métaboliques des maladies cardiovasculaires” à l’Inserm U970, poursuit : “Cette collaboration nous a permis de démontrer pour la première fois le rôle de la voie TREM-1 dans les maladies cardiovasculaires et ouvre des perspectives enthousiasmantes pour des développement scientifiques et thérapeutiques pour des maladies pour lesquelles existe un important besoin médical ”.
Pour Catherine Guillemin, Présidente de SAYENS (ex. SATT Grand Est), qui représente les intérêts de l’Université de Lorraine dans la préparation de cet accord commercial, commente : “Cet accord a pu être réalisé grâce à la collaboration étroite et les négociations constructives entre Inserm Transfert et SAYENS, ce qui a permis un alignement des intérêts de chacun au bénéfice d’une relation durable avec Inotrem”.
sTREM-1 est un marqueur de la sévérité et de l’évolution des patients souffrants d’infarctus du myocarde: des concentrations plasmatiques élevées de sTREM-1 après une attaque cardiaque sont associées à un risque trois fois supérieur de récurrence d’événement cardiaque ou de décès dans les deux ans qui suivent (références 1 and 2).
Inotrem a récemment annoncé des résultats prometteurs de Phase IIa dans le choc septique, renforçant ainsi l’approche de la société qui utilise les concentrations de sTREM-1 dans le sang comme biomarqueur potentiel pour identifier les patients les plus susceptibles de bénéficier du traitement à base de nangibotide, le premier candidat-médicament d’Inotrem. En plus de ces résultats positifs dans le domaine du choc septique, sTREM-1 a le potentiel d’être utilisé comme biomarqueur pour identifier les patients les plus à risque d’être concernés par un nouvel événement cardiaque.

A propos d’Inotrem
Inotrem S.A. est une société de biotechnologie spécialisée dans le contrôle de la réponse immunitaire au cours de maladies inflammatoires aigües, telles que le choc septique. La société a développé un nouveau concept d’immuno-modulation pour contrôler les perturbations des réponses inflammatoires. S’intéressant plus particulièrement à l’immunothérapie ciblée dans des contextes de soins intensifs, la société a été créée en 2013 par le Dr Jean-Jacques Garaud, ancien responsable de la R&D précoce du groupe Roche, le Pr Sébastien Gibot, et le Dr Marc Derive. Le produit leader d’Inotrem, nangibotide (LR12), ouvre la voie à des traitements personnalisés dans plusieurs indications thérapeutiques, telles que le choc septique et l’infarctus du myocarde. Inotrem est soutenue par des investisseurs européens de premier plan : Sofinnova Partners, Andera Partners, Biomed Invest et Inserm Transfert Initiative.
www.inotrem.com

A propos de sTREM-1 et la voie TREM-1
TREM-1 est un amplificateur de la réponse inflammatoire et a été initialement caractérisé pour son rôle dans la physiopathologie du choc septique, et d’autres maladies aigües telles que l’infarctus du myocarde. Soluble TREM-1 est une protéine plasmatique soluble libérée lors de l’activation de la voie TREM-1, et jouant ainsi le rôle de marqueur de l’activation de la voie TREM-1.

A propos de Nangibotide
Nangibotide est la formulation active de l’ingrédient LR12, un peptide synthétique visant à contrôler la boucle amplificatrice de la réponse inflammatoire par l’inhibition du récepteur TREM-1. Plusieurs modèles précliniques du choc septique permettent de documenter l’efficacité thérapeutique de LR12 dans différentes espèces, qui ont montré une réponse inflammatoire équilibrée, une amélioration des paramètres hémodynamiques et de la survie.

Références
1- Boufenzer et al, TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circulation Research 2015 May 22.
Download at https://www.inotrem.com/wp-content/uploads/2018/09/Boufenzer_Circ-Res-2015.pdf
2- Jérémie Lemarie, Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Failure 2015.
Download at: https://www.inotrem.com/wp-content/uploads/2018/09/Lemarie_2015-ESC_Heart_Failure.pdf

31/01/2019

Paris, January 31st, 2019. Inotrem S.A., a biotechnology company focused on the modulation of the TREM-1 pathway for the management of acute and chronic inflammatory syndromes, announced today the signature of an exclusive license agreement with four major research organizations, under which it receives the exclusive worldwide rights for the biomarker soluble TREM-1 (sTREM-1) in cardiovascular diseases, and in particular acute myocardial infarction. The academic partners are Universities of Paris Sorbonne and of Lorraine, Inserm, and AP-HP.
As of today, Inotrem owns exclusive rights for sTREM-1 in septic shock and cardiovascular diseases. This agreement will enable Inotrem to commercialize or sublicense for these indications any resulting test developed for sTREM-1.
Jean-Jacques Garaud, CEO of Inotrem, comments: “This licensing agreement is an important step towards expanding our TREM-1 franchise from sepsis to cardiovascular diseases and consolidating our unique intellectual property position around the TREM-1 pathway, both from a therapeutic agent and personalized medicine perspective”.
Pr Hafid Ait Oufella, team leader “Immuno-metabolic mechanism of cardiovascular diseases” at Inserm (U970), comments: “This collaboration led to the first demonstration of the implication of TREM-1 in cardiovascular diseases and opens very promising avenues for research and therapeutic development in diseases with huge unmet medical need”.
For Catherine Guillemin, President of SAYENS (ex. SATT Grand Est), who represents the interests of Université de Lorraine in the preparation of this license agreement, comments: “This license agreement has been done thanks to the close collaboration and constructive negotiation between Inserm Transfert and SAYENS, which has undoubtedly enabled an alignment of interests that will be valuable for a long-term relationship with Inotrem”.
Soluble TREM-1 has been shown to be a reliable marker of severity and outcome of patients suffering from acute myocardial infarction: high sTREM-1 levels in blood following a heart attack is associated with a three-times higher risk of recurrence of further cardiovascular events or death in the following 2 years (references 1 and 2 below).
Inotrem has recently announced promising Phase IIa results in septic shock that support the company’s approach which uses soluble TREM-1 level in blood as a potential biomarker for the identification of patients who will most likely benefit from treatment by nangibotide, Inotrem lead drug candidate. On top of these promising results in the field of septic shock, sTREM-1 may thus have a strong value as a standalone biomarker for the identification of patients at risk of secondary events following a heart attack.

About Inotrem
Inotrem S.A. is a biotechnology company specialized in for the control of acute inflammatory syndromes, such as septic shock. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European investors — Sofinnova Partners, Andera Partners, Biomed Invest and Inserm Transfert Initiative.
www.inotrem.com

About sTREM-1 and TREM-1 pathway.
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction. Soluble TREM-1 (sTREM-1) is a plasma circulating protein with is released upon TREM-1 activation, and is thus a marker of TREM-1 pathway activation.

About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.

References
1- Boufenzer et al, TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circulation Research 2015 May 22.
Download at https://www.inotrem.com/wp-content/uploads/2018/09/Boufenzer_Circ-Res-2015.pdf
2- Jeremie Lemarie, Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Failure 2015.
Download at: https://www.inotrem.com/wp-content/uploads/2018/09/Lemarie_2015-ESC_Heart_Failure.pdf